Jacobs Levy Equity Management’s Precigen PGEN Stock Holding History

Jacobs Levy Equity Management’s Portfolio PGEN Stock Details PGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-373,013	Closed	-$500K	–	1025
2023 Q4	$500K	Sell	373,013 -314,781	-46%	-$370K	﹤0.01%	826
2023 Q3	$977K	Sell	687,794 -666,781	-49%	-$945K	0.01%	684
2023 Q2	$1.56M	Sell	1,354,575 -660,319	-33%	-$780K	0.01%	616
2023 Q1	$2.14M	Buy	+2,014,894	New	+$2.91M	0.01%	562
2022 Q4	–	Sell	-234,400	Closed	-$497K	–	1017
2022 Q3	$497K	Sell	234,400 -518,641	-69%	-$1.09M	﹤0.01%	832
2022 Q2	$1.01M	Buy	+753,041	New	+$1.12M	0.01%	753
2021 Q3	–	Sell	-11,359	Closed	-$74K	–	1107
2021 Q2	$74K	Buy	+11,359	New	+$79.4K	﹤0.01%	1014
2020 Q1	–	Sell	-1,086,040	Closed	-$5.95M	–	1070
2019 Q4	$5.95M	Buy	+1,086,040	New	+$6.11M	0.06%	340
2016 Q3	–	Sell	-94,796	Closed	-$2.31M	–	1096
2016 Q2	$2.31M	Buy	+94,796	New	+$2.69M	0.05%	396

Other funds holding PGEN

PCM

Patient Capital Management Baltimore, Maryland $2.74B AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jacobs Levy Equity Management's PGEN Position: Q1 2024 in Review

Jacobs Levy Equity Management sold out of Precigen (PGEN) in Q1 2024, closing a stake of 373,013 shares — an estimated $500K sold.

Jacobs Levy Equity Management first reported a position in PGEN in Q2 2016 and held it in 9 quarters. The position peaked at $5.95M in Q4 2019. 130 funds tracked by Wall St. Rank hold PGEN as of Q1 2024.

Jacobs Levy Equity Management reported no remaining Precigen position as of Q1 2024 after selling out during the quarter.
Jacobs Levy Equity Management sold 373,013 Precigen shares in Q1 2024, an estimated $500K.
Jacobs Levy Equity Management first reported a position in Precigen in Q2 2016 and held it in 9 quarters.
Jacobs Levy Equity Management's Precigen position peaked at $5.95M in Q4 2019.
130 funds tracked by Wall St. Rank held Precigen as of Q1 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2024, filed 15 May 2024.